After becoming a household name during the COVID-19 pandemic, Moderna (ticker: MRNA) is attempting a second act: transforming its mRNA technology into a broader biotech platform. With its COVID vaccine revenue declining sharply from pandemic highs, the company is racing to prove it can diversify and innovate. For traders, 2025 could be a pivotal year.
The post-COVID revenue dip
Moderna’s total revenue dropped significantly after 2022, falling from $18.4 billion in 2021 to under $6 billion in 2024. As COVID-19 vaccinations became less frequent and governments reduced stockpiling, Moderna’s dependence on its flagship product became an apparent vulnerability.
To maintain investor confidence, the company has pivoted toward a more diversified pipeline. In particular, its research into cancer vaccines, flu shots, RSV, and personalised immunotherapy has caught attention.
Cancer vaccine progress
One of the most closely followed developments is Moderna’s personalised cancer vaccine, which it is developing in partnership with Merck. Early-stage trials in melanoma patients have shown promising results, and Phase 3 studies are expected to expand in 2025. If successful, this could become one of the first commercialised cancer vaccines based on mRNA technology, potentially a multi-billion-dollar market.
Traders typically monitor regulatory updates, trial timelines, and partnership announcements with Merck as leading indicators for momentum in the stock.
Flu and RSV competition
Moderna is also targeting seasonal illnesses. Its flu vaccine (mRNA-1010) is in late-stage trials, as is its RSV vaccine. The challenge here is not only clinical success but also competition. Pfizer and GSK already have RSV products on the market. Moderna must prove its formulations are either more effective or easier to distribute — ideally, both.
Watch for FDA decisions and launch strategies in the U.S. and EU, as these could impact revenue forecasts and sentiment around the stock.
AI and accelerated R&D
In 2025, Moderna is integrating AI and machine learning into its drug development cycle. The company claims this shortens the time from lab concept to human trials. This is particularly important for infectious diseases and oncology, where speed can provide competitive advantages.
Moderna’s collaborations with AI companies and supercomputing projects are part of its broader pitch to investors: that it is a platform biotech firm, not just a vaccine company.
Financials and cash position
Despite reduced revenue, Moderna still has a strong balance sheet. It ended 2024 with approximately $13 billion in cash and marketable securities. This financial buffer allows it to fund clinical trials and acquisitions without immediate dilution risk.
The company also announced a $3 billion share buyback program — a signal to investors that it believes the stock is undervalued.
Key risks to consider
Traders should not ignore the risks. Regulatory setbacks, competitive pressure, and slow adoption of new vaccines can weigh on performance. In addition, biotech stocks are sensitive to broader macro sentiment, especially interest rates and sector rotation.
Capitalise on volatility in share markets
Take a position on moving share prices. Never miss an opportunity.
71% of retail CFD accounts lose money.
Bottom line
Moderna in 2025 is no longer a pure COVID play. With a diversified pipeline, strong cash reserves, and growing R&D capabilities, the company is attempting to reposition itself as a leading platform biotech stock. For traders, the potential is real — but so are the risks. Focus on clinical trial updates, earnings calls, and sector sentiment to navigate $MRNA effectively.
Past performance does not guarantee or predict future performance. This article is offered for general information purposes only and does not constitute investment advice.
